Anti-SorLA/SORL1 antibody (ab22814)
Key features and details
- Goat polyclonal to SorLA/SORL1
- Suitable for: ICC/IF
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-SorLA/SORL1 antibody
See all SorLA/SORL1 primary antibodies -
Description
Goat polyclonal to SorLA/SORL1 -
Host species
Goat -
Tested Applications & Species
Application Species ICC/IF Human -
Immunogen
Synthetic peptide corresponding to Human SorLA/SORL1 aa 2203-2214 (C terminal).
Sequence:TGFSDDVPMVIA
-
Positive control
- Mouse brain lysate
-
General notes
This product was previously labelled as SorLA
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
Storage buffer
pH: 7.30
Preservative: 0.02% Sodium azide
Constituents: Tris buffered saline, 0.5% BSA -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Purification notes
ab22814 is purified by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab22814 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Tested applications are guaranteed to work and covered by our Abpromise guarantee.
Predicted to work for this combination of applications and species but not guaranteed.
Does not work for this combination of applications and species.
Application | Species |
---|---|
ICC/IF |
Human
|
All applications |
Rat
Rabbit
Cow
Dog
|
Application | Abreviews | Notes |
---|---|---|
ICC/IF |
Use a concentration of 10 µg/ml.
|
Notes |
---|
ICC/IF
Use a concentration of 10 µg/ml. |
Target
-
Function
Likely to be a multifunctional endocytic receptor, that may be implicated in the uptake of lipoproteins and of proteases. Binds LDL, the major cholesterol-carrying lipoprotein of plasma, and transports it into cells by endocytosis. Binds the receptor-associated protein (RAP). Could play a role in cell-cell interaction. -
Tissue specificity
Expressed mainly in brain, where it is most abundant in the cerebellum, cerebral cortex and the occipital pole; low expression in the putamen and the thalamus. According to PubMed:9157966, found in spinal cord, testis, liver, kidney and pancreas with detectable levels in placenta, lung and heart. According to PubMed:8940146, expressed in the prostate, ovary, thyroid and spleen, but not found in kidney, liver, lung, skeletal muscle, bone marrow and adrenals. -
Sequence similarities
Belongs to the SORL1 family.
Contains 5 BNR repeats.
Contains 1 EGF-like domain.
Contains 6 fibronectin type-III domains.
Contains 11 LDL-receptor class A domains.
Contains 5 LDL-receptor class B repeats. -
Post-translational
modificationsThe propeptide removed in the N-terminus may be cleaved by furin or homologous proteases. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 6653 Human
- Entrez Gene: 300652 Rat
- Omim: 602005 Human
- SwissProt: Q92673 Human
- SwissProt: Q9R0N2 Rat
- Unigene: 368592 Human
-
Alternative names
- C11orf32 antibody
- FLJ21930 antibody
- FLJ39258 antibody
see all
Images
-
Immunocytochemistry/ Immunofluorescence of HepG2 staining SorLA/SORL1 using ab22814 at 10 μg/ml followed by Alexa Fluor 488 secondary antibody 2 μg/ml
The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 μg/ml) followed by Alexa Fluor 488 secondary antibody (2 μg/ml).
-
Immunocytochemistry/ Immunofluorescence of A431 staining SorLA/SORL1 using ab22814 at 10 μg/ml followed by Alexa Fluor 488 secondary antibody 2 μg/ml
The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 μg/ml) followed by Alexa Fluor 488 secondary antibody (2 μg/ml).
Datasheets and documents
References (0)
ab22814 has not yet been referenced specifically in any publications.